GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (CHIX:PEGc) » Definitions » Earnings per Share (Diluted)

Pharma Equity Group A/S (CHIX:PEGC) Earnings per Share (Diluted) : kr-0.17 (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pharma Equity Group A/S Earnings per Share (Diluted)?

Pharma Equity Group A/S's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was kr-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.17.

Pharma Equity Group A/S's EPS (Basic) for the three months ended in Dec. 2023 was kr-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.17.

Pharma Equity Group A/S's EPS without NRI for the three months ended in Dec. 2023 was kr-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.17.

During the past 3 years, the average EPS without NRIGrowth Rate was 67.80% per year.

During the past 13 years, Pharma Equity Group A/S's highest 3-Year average EPS without NRI Growth Rate was 85.40% per year. The lowest was -367.20% per year. And the median was 43.25% per year.


Pharma Equity Group A/S Earnings per Share (Diluted) Historical Data

The historical data trend for Pharma Equity Group A/S's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Earnings per Share (Diluted) Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.70 -1.04 0.10 -0.01 -0.02

Pharma Equity Group A/S Quarterly Data
Mar16 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.15 - - -0.01

Competitive Comparison of Pharma Equity Group A/S's Earnings per Share (Diluted)

For the Biotechnology subindustry, Pharma Equity Group A/S's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's PE Ratio falls into.



Pharma Equity Group A/S Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Pharma Equity Group A/S's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-24.609-0)/1088.551
=-0.02

Pharma Equity Group A/S's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-13.007-0)/1336.705
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Pharma Equity Group A/S  (CHIX:PEGc) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pharma Equity Group A/S Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (CHIX:PEGC) Business Description

Traded in Other Exchanges
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.

Pharma Equity Group A/S (CHIX:PEGC) Headlines

No Headlines